Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic - PubMed (original) (raw)
. 2021 Jan 15;371(6526):288-292.
doi: 10.1126/science.abe9728. Epub 2020 Dec 8.
Carlos A Prete Jr # 2, Claudia M M Abrahim # 3, Alfredo Mendrone Jr # 4 5, Tassila Salomon # 6 7, Cesar de Almeida-Neto 4 5, Rafael F O França 8, Maria C Belotti 2, Maria P S S Carvalho 3, Allyson G Costa 3, Myuki A E Crispim 3, Suzete C Ferreira 4 5, Nelson A Fraiji 3, Susie Gurzenda 9, Charles Whittaker 10, Leonardo T Kamaura 11, Pedro L Takecian 11, Pedro da Silva Peixoto 11, Marcio K Oikawa 12, Anna S Nishiya 4 5, Vanderson Rocha 4 5, Nanci A Salles 4, Andreza Aruska de Souza Santos 13, Martirene A da Silva 3, Brian Custer 14 15, Kris V Parag 16, Manoel Barral-Netto 17, Moritz U G Kraemer 18, Rafael H M Pereira 19, Oliver G Pybus 18, Michael P Busch 14 15, Márcia C Castro 9, Christopher Dye 18, Vítor H Nascimento 2, Nuno R Faria 20 16 18, Ester C Sabino 20
Affiliations
- PMID: 33293339
- PMCID: PMC7857406
- DOI: 10.1126/science.abe9728
Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic
Lewis F Buss et al. Science. 2021.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly in Manaus, the capital of Amazonas state in northern Brazil. The attack rate there is an estimate of the final size of the largely unmitigated epidemic that occurred in Manaus. We use a convenience sample of blood donors to show that by June 2020, 1 month after the epidemic peak in Manaus, 44% of the population had detectable immunoglobulin G (IgG) antibodies. Correcting for cases without a detectable antibody response and for antibody waning, we estimate a 66% attack rate in June, rising to 76% in October. This is higher than in São Paulo, in southeastern Brazil, where the estimated attack rate in October was 29%. These results confirm that when poorly controlled, COVID-19 can infect a large proportion of the population, causing high mortality.
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Figures
Fig. 1. Abbott SARS-CoV-2 N IgG chemiluminescence assay performance and antibody dynamics in different clinical samples.
(A) Signal-to-cutoff (S/C) values using the Abbott chemiluminescence assay (CMIA) in the following clinical samples (from left to right): 821 routine blood donation samples from Manaus in February 2020, >1 month before the first notified case in the city; 49 samples collected at 20 to 33 days after symptom onset from SARS-CoV-2 PCR-positive patients in São Paulo requiring hospital care; 193 patients in São Paulo with PCR-confirmed symptomatic COVID-19 not requiring hospital care, with plasma donation samples taken in the early convalescent period; 107 samples from the same nonhospitalized plasma donor cohort from the late convalescent period; 133 samples that tested positive on either the Abbott CMIA or the Roche Elecsys assay out of 1000 routine blood donations collected in July 2020 and tested in parallel from the Fundação Pró-Sangue blood center (São Paulo). Upper dashed line denotes the manufacturer’s threshold for positive result of 1.4 S/C; lower dashed line denotes an alternative threshold of 0.4 S/C. In the box plots of Abbott IgG CMIA S/C, the central line is the median; upper and lower hinges are the 25th and 75th centiles, respectively; whiskers show the range, extending to a maximum of 1.5 times the interquartile range from the hinge. (B) S/C values of the Abbott CMIA for 104 convalescent plasma donors who were sampled at two different times. (C) Histogram of the slopes among 88 individuals shown in (B) who tested positive (>1.4 S/C) at the first time point. POS, post–onset of symptoms.
Fig. 2. Monthly antibody prevalence and signal-to-cutoff (S/C) reading in Manaus and São Paulo.
(A and C) SARS-CoV-2 antibody prevalence estimates in Manaus (A) and São Paulo (C) with a range of corrections, from left to right: reweighting positive tests, at positivity threshold of 1.4 S/C, to the age and sex distribution of each city; further correcting for sensitivity and specificity at this assay threshold; reweighting positive tests for age and sex at a reduced threshold of 0.4 S/C; correcting for sensitivity and specificity at this threshold; and finally correcting for seroreversion. Error bars are 95% confidence intervals. Gray bars are standardized daily mortality using confirmed COVID-19 deaths from the SIVEP-Gripe (Sistema de Informação de Vigilância Epidemiológica da Gripe;
) notification system and standardized by the direct method using the total projected Brazilian population for 2020 as reference. Black lines are rescaled cumulative deaths, such that the maximum is set to the maximum seroprevalence estimate for each city. Mortality data are plotted according to the date of death. (B and D) Distribution of S/C values over the nine monthly samples are shown for Manaus (B) and São Paulo (D). Each point represents the S/C reading for a single donation sample. Upper dashed line denotes the manufacturer’s threshold (1.4 S/C units); lower dashed line denotes an alternative threshold (0.4 S/C units); black box plots show the median (central lines), interquartile range (hinges), and range extending to 1.5 times the interquartile range from each hinge (whiskers) of S/C values above 0.4 (i.e., excluding very low and likely true-negative values).
Comment in
- Herd immunity by infection is not an option.
Sridhar D, Gurdasani D. Sridhar D, et al. Science. 2021 Jan 15;371(6526):230-231. doi: 10.1126/science.abf7921. Science. 2021. PMID: 33446540 No abstract available.
Similar articles
- High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.
Lalwani P, Araujo-Castillo RV, Ganoza CA, Salgado BB, Pereira Filho IV, da Silva DSS, de Morais TBDN, Jordão MF, Ortiz JV, Barbosa ARC, Sobrinho WBS, Cordeiro IB, de Souza Neto JN, de Assunção EN, da Costa CF, de Souza PE, de Albuquerque BC, Astofi-Filho S; DETECTCoV-19 Study Team; Lalwani JDB. Lalwani P, et al. Lancet Glob Health. 2021 Nov;9(11):e1508-e1516. doi: 10.1016/S2214-109X(21)00355-7. Lancet Glob Health. 2021. PMID: 34678195 Free PMC article. - Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population.
Bichara CDA, da Silva Graça Amoras E, Vaz GL, da Silva Torres MK, Queiroz MAF, do Amaral IPC, Vallinoto IMVC, Bichara CNC, Vallinoto ACR. Bichara CDA, et al. BMC Infect Dis. 2021 May 15;21(1):443. doi: 10.1186/s12879-021-06156-x. BMC Infect Dis. 2021. PMID: 33992073 Free PMC article. - SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study.
Prete CA Jr, Buss LF, Whittaker C, Salomon T, Oikawa MK, Pereira RHM, Moura ICG, Delerino L, Barral-Netto M, Tavares NM, Franca RFO, Boaventura VS, Miyajima F, Mendrone-Junior A, de Almeida-Neto C, Salles NA, Ferreira SC, Fladzinski KA, de Souza LM, Schier LK, Inoue PM, Xabregas LA, Crispim MAE, Fraiji N, Araujo FLV, Carlos LMB, Pessoa V, Ribeiro MA, de Souza RE, da Silva SMN, Cavalcante AF, Valença MIB, da Silva MV, Lopes E, Filho LA, Mateos SOG, Nunes GT, Silva-Junior AL, Busch MP, Castro MC, Dye C, Ratmann O, Faria NR, Nascimento VH, Sabino EC. Prete CA Jr, et al. Elife. 2022 Sep 22;11:e78233. doi: 10.7554/eLife.78233. Elife. 2022. PMID: 36135358 Free PMC article. - Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
Wendel S, Kutner JM, Machado R, Fontão-Wendel R, Bub C, Fachini R, Yokoyama A, Candelaria G, Sakashita A, Achkar R, Hamerschlak N, Scuracchio P, Amaral M, Dal Ben M, Araujo D, Soares C, Camargo A, Kallás E, Durigon E, Reis LF, Rizzo LV. Wendel S, et al. Transfusion. 2020 Dec;60(12):2938-2951. doi: 10.1111/trf.16065. Epub 2020 Sep 16. Transfusion. 2020. PMID: 32935877 Free PMC article. - Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19).
Kislaya I, Gonçalves P, Barreto M, Sousa R, Garcia AC, Matos R, Guiomar R, Rodrigues AP; ISNCOVID-19 Group. Kislaya I, et al. Acta Med Port. 2021 Feb 1;34(2):87-94. doi: 10.20344/amp.15122. Epub 2021 Feb 1. Acta Med Port. 2021. PMID: 33641702
Cited by
- Randomised Badger Culling Trial lacks evidence for proactive badger culling effect on tuberculosis in cattle: comment on Mills et al. 2024, Parts I & II.
Torgerson PR, Hartnack S, Rasmussen P, Lewis F, O'Donnell P, Langton T. Torgerson PR, et al. bioRxiv [Preprint]. 2024 Sep 20:2024.09.18.613634. doi: 10.1101/2024.09.18.613634. bioRxiv. 2024. PMID: 39345529 Free PMC article. Preprint. - Effects of mobility, immunity and vaccination on SARS-CoV-2 transmission in the Dominican Republic: a modelling study.
Finch E, Nilles EJ, Paulino CT, Skewes-Ramm R, Lau CL, Lowe R, Kucharski AJ. Finch E, et al. Lancet Reg Health Am. 2024 Aug 30;37:100860. doi: 10.1016/j.lana.2024.100860. eCollection 2024 Sep. Lancet Reg Health Am. 2024. PMID: 39281423 Free PMC article. - Seroprevalence trends of anti-SARS-CoV-2 antibodies in the adult population of the São Paulo Municipality, Brazil: Results from seven serosurveys from June 2020 to April 2022. The SoroEpi MSP Study.
Tess BH, Turchi Martelli CM, Goi Porto Alves MC, Cortes F, Ivata Bernal RT, Vieira de Souza W, de Albuquerque Luna EJ, da Cunha Rodrigues L, Cavallari Nunes M, de Castro Reinach F, Granato CFH, Rizzatti EG, Tostes Pintão MC. Tess BH, et al. PLoS One. 2024 Aug 26;19(8):e0309441. doi: 10.1371/journal.pone.0309441. eCollection 2024. PLoS One. 2024. PMID: 39186722 Free PMC article. - Detection of Nucleocapsid Antibodies Associated with Primary SARS-CoV-2 Infection in Unvaccinated and Vaccinated Blood Donors.
Grebe E, Stone M, Spencer BR, Akinseye A, Wright D, Di Germanio C, Bruhn R, Zurita KG, Contestable P, Green V, Lanteri MC, Saa P, Biggerstaff BJ, Coughlin MM, Kleinman S, Custer B, Jones JM, Busch MP. Grebe E, et al. Emerg Infect Dis. 2024 Aug;30(8):1621-1630. doi: 10.3201/eid3008.240659. Epub 2024 Jul 9. Emerg Infect Dis. 2024. PMID: 38981189 Free PMC article. - COVID-19 seroprevalence cohort survey among health care workers and their household members in Kinshasa, DR Congo, 2020-2022.
Madinga J, Mbala-Kingebeni P, Nkuba-Ndaye A, Baketana-Kinzonzi L, Matungulu-Biyala E, Mutombo-Lupola P, Seghers CA, Smekens T, Ariën KK, Van Damme W, Kalk A, Peeters M, Ahuka-Mundeke S, Muyembe-Tamfum JJ, Vanlerberghe V. Madinga J, et al. J Health Popul Nutr. 2024 Jun 1;43(1):74. doi: 10.1186/s41043-024-00536-0. J Health Popul Nutr. 2024. PMID: 38824595 Free PMC article.
References
- Hallal P. C., Hartwig F. P., Horta B. L., Silveira M. F., Struchiner C. J., Vidaletti L. P., Neumann N. A., Pellanda L. C., Dellagostin O. A., Burattini M. N., Victora G. D., Menezes A. M. B., Barros F. C., Barros A. J. D., Victora C. G., SARS-CoV-2 antibody prevalence in Brazil: Results from two successive nationwide serological household surveys. Lancet Glob. Health 8, e1390–e1398 (2020). 10.1016/S2214-109X(20)30387-9 - DOI - PMC - PubMed
- Candido D. da S., Claro I. M., de Jesus J. G., Souza W. M., Moreira F. R. R., Dellicour S., Mellan T. A., du Plessis L., Pereira R. H. M., Sales F. C. S., Manuli E. R., Thézé J., Almeida L., Menezes M. T., Voloch C. M., Fumagalli M. J., Coletti T. M., da Silva C. A. M., Ramundo M. S., Amorim M. R., Hoeltgebaum H. H., Mishra S., Gill M. S., Carvalho L. M., Buss L. F., Prete C. A., Ashworth J., Nakaya H. I., Peixoto P. S., Brady O. J., Nicholls S. M., Tanuri A., Rossi Á. D., Braga C. K. V., Gerber A. L., Guimarães A. P. de C., Gaburo N., Alencar C. S., Ferreira A. C. S., Lima C. X., Levi J. E., Granato C., Ferreira G. M., Francisco R. S., Granja F., Garcia M. T., Moretti M. L., Perroud M. W., Castiñeiras T. M. P. P., Lazari C. S., Hill S. C., de Souza-Santos A. A., Simeoni C. L., Forato J., Sposito A. C., Schreiber A. Z., Santos M. N. N., de Sá C. Z., Souza R. P., Resende-Moreira L. C., Teixeira M. M., Hubner J., Leme P. A. F., Moreira R. G., Nogueira M. L., Brazil-UK Centre for Arbovirus Discovery, Diagnosis, Genomics and Epidemiology (CADDE) Genomic Network, Ferguson N. M., Costa S. F., Proenca-Modena J. L., Vasconcelos A. T. R., Bhatt S., Lemey P., Wu C.-H., Rambaut A., Loman N. J., Aguiar R. S., Pybus O. G., Sabino E. C., Faria N. R., Evolution and epidemic spread of SARS-CoV-2 in Brazil. Science 369, 1255–1260 (2020). 10.1126/science.abd2161 - DOI - PMC - PubMed
- de Souza W. M., Buss L. F., Candido D. da S., Carrera J.-P., Li S., Zarebski A. E., Pereira R. H. M., Prete C. A. Jr.., de Souza-Santos A. A., Parag K. V., Belotti M. C. T. D., Vincenti-Gonzalez M. F., Messina J., da Silva Sales F. C., Andrade P. D. S., Nascimento V. H., Ghilardi F., Abade L., Gutierrez B., Kraemer M. U. G., Braga C. K. V., Aguiar R. S., Alexander N., Mayaud P., Brady O. J., Marcilio I., Gouveia N., Li G., Tami A., de Oliveira S. B., Porto V. B. G., Ganem F., de Almeida W. A. F., Fantinato F. F. S. T., Macário E. M., de Oliveira W. K., Nogueira M. L., Pybus O. G., Wu C.-H., Croda J., Sabino E. C., Faria N. R., Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil. Nat. Hum. Behav. 4, 856–865 (2020). 10.1038/s41562-020-0928-4 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- MC_PC_19012/MRC_/Medical Research Council/United Kingdom
- MR/R015600/1/MRC_/Medical Research Council/United Kingdom
- HHSN268201100007C/HL/NHLBI NIH HHS/United States
- MR/S019510/1/MRC_/Medical Research Council/United Kingdom
- HHSN268201100007I/HL/NHLBI NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous